21:44 , Mar 22, 2019 |  BC Extra  |  Clinical News

After aducanumab failure, Eisai to test another anti-amyloid mAb

With the announcement that Eisai plans to start yet another Phase III trial of an anti-amyloid candidate, Alzheimer's disease researcher Rudolph Tanzi told BioCentury he wouldn't enroll any more AD patients in trials of therapies...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

ALZT-OP1: Phase III started

AZTherapies began the double-blind, placebo-controlled, international Phase III trial to compare ALZT-OP1 vs. each of its components -- inhaled cromolyn and oral ibuprofen -- in about 600 patients. The company has an SPA from FDA...